{"id":"azd5153","phase":"phase_1","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"}]},"status":"active","trials":["NCT03527147","NCT03205176"],"aliases":["BRD4 inhibitor"],"patents":[],"pricing":[],"timeline":[],"aiSummary":"AZD5153 is a selective BET bromodomain inhibitor that disrupts the interaction between bromodomains and acetylated histones, leading to changes in gene expression. Used for Relapsed or refractory hematologic malignancies.","brandName":"AZD5153","companyId":"acerta-pharma-bv","mechanism":{"_ai_source":"featherless-qwen","explanation":"BET bromodomain inhibitors like AZD5153 block the binding of BET proteins to acetylated histones, which modulates the transcription of genes involved in cell proliferation and survival, particularly in cancer cells.","oneSentence":"AZD5153 is a selective BET bromodomain inhibitor that disrupts the interaction between bromodomains and acetylated histones, leading to changes in gene expression.","_ai_confidence":"medium"},"commercial":null,"companyName":"Acerta Pharma BV","competitors":[],"genericName":"AZD5153","indications":{"approved":[{"name":"Relapsed or refractory hematologic malignancies"}]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}